Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2021

Open Access 01-12-2021 | Magnetic Resonance Imaging | Case report

A late systemic and brain metastasis from subcutaneous leiomyosarcoma of the right forearm: a case report and review of the literature

Authors: Eric Dietel, Ulf Nestler, Hans Nenning, Christian Eisenlöffel, Ruth Stassart, Jürgen Meixensberger

Published in: Journal of Medical Case Reports | Issue 1/2021

Login to get access

Abstract

Background

Leiomyosarcomas are rare malignant tumors which originate from smooth muscle cells and very seldom give rise to intracerebral metastases. Nearly all cases of intracranial metastases stem from leiomyosarcomas of the uterus. We present a 61-year-old Caucasian man who developed multiple intracranial and extracranial metastases from leiomyosarcoma of the right forearm, diagnosed and treated 9 years before the current presentation.

Case presentation

The Caucasian patient presented to the emergency department due to a progressive hemiparesis on the left side. Magnetic resonance imaging scans of the neurocranium showed multiple intracerebral masses with perifocal edema. One of these was located in the right parietal lobe, corresponding to the hemiparesis. The patient underwent microsurgical complete resection of the parietal mass and was subsequently subjected to further radiotherapy. Histopathological studies revealed metastasis of the former leiomyosarcoma.

Conclusions

Leiomyosarcomas represent a rare entity of mesenchymal tumors. Intracerebral metastasis of these tumors is even less frequent. This case shows the importance of long-term follow-up in patients with leiomyosarcoma.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, et al. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun. 2018;9(1):144.CrossRef Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, et al. Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun. 2018;9(1):144.CrossRef
2.
go back to reference Singhi EK, Moore DC, Muslimani A. Metastatic soft tissue sarcomas: a review of treatment and new pharmacotherapies. P T. 2018;43(7):410–29.PubMedPubMedCentral Singhi EK, Moore DC, Muslimani A. Metastatic soft tissue sarcomas: a review of treatment and new pharmacotherapies. P T. 2018;43(7):410–29.PubMedPubMedCentral
3.
go back to reference Gautschi OP, Hottinger AF, Lobrinus JA, Schaller K, Bijlenga P. Isolated cerebral metastasis of a triceps muscle leiomyosarcoma: a case report. Br J Neurosurg. 2014;28(3):400–2.CrossRef Gautschi OP, Hottinger AF, Lobrinus JA, Schaller K, Bijlenga P. Isolated cerebral metastasis of a triceps muscle leiomyosarcoma: a case report. Br J Neurosurg. 2014;28(3):400–2.CrossRef
4.
go back to reference Sheng JY, Movva S. Systemic therapy for advanced soft tissue sarcoma. Surg Clin North Am. 2016;96(5):1141–56.CrossRef Sheng JY, Movva S. Systemic therapy for advanced soft tissue sarcoma. Surg Clin North Am. 2016;96(5):1141–56.CrossRef
5.
go back to reference Tap WD, Wagner AJ, Papai Z, Ganjoo KN, Yen C-C, Schoffski P, et al. ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). JCO. 2019;37(18_suppl):LBA3.CrossRef Tap WD, Wagner AJ, Papai Z, Ganjoo KN, Yen C-C, Schoffski P, et al. ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). JCO. 2019;37(18_suppl):LBA3.CrossRef
6.
go back to reference Berry V, Basson L, Bogart E, Mir O, Blay J-Y, Italiano A, et al. REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma—a quality-adjusted time without symptoms of progression or toxicity analysis. Cancer. 2017;123(12):2294–302.CrossRef Berry V, Basson L, Bogart E, Mir O, Blay J-Y, Italiano A, et al. REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma—a quality-adjusted time without symptoms of progression or toxicity analysis. Cancer. 2017;123(12):2294–302.CrossRef
7.
go back to reference Coindre J-M, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchre D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. Cancer. 2001;91(10):1914–26.CrossRef Coindre J-M, Terrier P, Guillou L, Le Doussal V, Collin F, Ranchre D, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas. Cancer. 2001;91(10):1914–26.CrossRef
8.
go back to reference Zagars GK, Ballo MT, Pisters PWT, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97(10):2530–43.CrossRef Zagars GK, Ballo MT, Pisters PWT, Pollock RE, Patel SR, Benjamin RS, et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer. 2003;97(10):2530–43.CrossRef
Metadata
Title
A late systemic and brain metastasis from subcutaneous leiomyosarcoma of the right forearm: a case report and review of the literature
Authors
Eric Dietel
Ulf Nestler
Hans Nenning
Christian Eisenlöffel
Ruth Stassart
Jürgen Meixensberger
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2021
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-020-02625-0

Other articles of this Issue 1/2021

Journal of Medical Case Reports 1/2021 Go to the issue